Hepatitis

We’re looking forward to the upcoming 31st Conference on Retroviruses and Opportunistic Infections (CROI) which is taking place in Denver, Colorado between 3-6 March 2024.  Promising attendees an opportunity to explore the latest technologies, treatments and products in the field of infectious diseases, we are excited to provide independent, expert video coverage of key data. […]

Despite being the most severe form of viral hepatitis, there is no FDA-approved therapy for chronic hepatitis delta (CHD).1 Patients with CHD can progress to cirrhosis, as early as 5–10 years after infection. Further complications can also develop, such as esophageal and gastric variceal bleeding, ascites, infections and liver cancer. The results of the phase III […]

Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key findings of the campaign and unanswered questions, are discussed by Dr Iza Ciglenecki […]

A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease, and what is […]

There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]

Dr Marina Klein (McGill University Health Centre, Montreal, Canada) joins touchINFECTIOUS DISEASES to discuss triple elimination of three infections (HIV, HBV and HCV) prevalent in low- and middle-income countries. Dr Klein highlights the challenges of transmission of HIV, hepatitis B and hepatitis C. She also looks current therapies for HIV, the elimination of Hepatitis C, […]

The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs dolutegravir plus FTC and TDF. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins […]

HIV/HBV co-infection increases the morbidity and mortality beyond those caused by either infection alone and there are number of challenges in it’s treatment. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins touchINFECTIOUS DISEASES to discuss the incidence of HIV/HBV co infection as well as the challenges in it’s treatment. The presentation […]

An estimated 354 million people worldwide live with hepatitis B or C, and for most, testing and treatment remain beyond reach. Consequently, the World Health Organization (WHO) has set the goal of eliminating hepatitis B and C by 2030. Dr Nicole Seguy (Regional Advisor HIV, hepatitis and STIs, WHO/Europe) summarizes the existing landscape of hepatitis […]